Asset Details
Do you wish to reserve the book?
Randomized Controlled Trial of Insulin Pump Therapy in Young Children With Type 1 Diabetes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Randomized Controlled Trial of Insulin Pump Therapy in Young Children With Type 1 Diabetes
Do you wish to request the book?
Randomized Controlled Trial of Insulin Pump Therapy in Young Children With Type 1 Diabetes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Randomized Controlled Trial of Insulin Pump Therapy in Young Children With Type 1 Diabetes
2005
Overview
OBJECTIVE:--This study assesses the effects of insulin pump therapy on diabetes control and family life in children 1-6 years old with type 1 diabetes. RESEARCH DESIGN AND METHODS--Twenty-six children with type 1 diabetes for [>/=]6 months were randomly assigned to current therapy (two or three shots per day using NPH insulin and rapid-acting analog) or continuous subcutaneous insulin infusion (CSII) for 6 months. After 6 months, current therapy subjects were offered CSII. Changes in HbA[subscript 1c], mean blood glucose (MBG), hypoglycemia frequency, diabetes-related quality of life (QOL), and parental adjustment were recorded. RESULTS:--Eleven subjects from each group completed the trial (age 46.3 ± 3.2 months [means ± SE]). At baseline, there were no differences between groups in HbA[subscript 1c], MBG, age, sex, diabetes duration, or parental QOL. Mean HbA[subscript 1c], MBG, and parental QOL were similar between groups at 6 months. Mean HbA[subscript 1c] and MBG did not change from baseline to 6 months in either group. The frequency of severe hypoglycemia, ketoacidosis, or hospitalization was similar between groups at any time period. Subjects on CSII had more fasting and predinner mild/moderate hypoglycemia at 1 and 6 months. Diabetes-related QOL improved in CSII fathers from baseline to 6 months. Psychological distress increased in current therapy mothers from baseline to 6 months. All subjects continued CSII after study completion. CONCLUSIONS:--CSII is safe and well tolerated in young children with diabetes and may have positive effects on QOL. CSII did not improve diabetes control when compared with injections, despite more mild/moderate hypoglycemia. The benefits and realistic expectations of CSII should be thoroughly examined before starting this therapy in very young children.
Publisher
American Diabetes Association
Subject
/ analysis
/ Biological and medical sciences
/ blood
/ children
/ Diabetes
/ Diabetes Mellitus, Type 1 - blood
/ Diabetes Mellitus, Type 1 - drug therapy
/ Diabetes Mellitus, Type 1 - physiopathology
/ Diabetes Mellitus, Type 1 - psychology
/ Diabetes. Impaired glucose tolerance
/ distress
/ Endocrine pancreas. Apud cells (diseases)
/ fasting
/ fathers
/ Female
/ Glycated Hemoglobin A - analysis
/ Humans
/ Hypoglycemic Agents - administration & dosage
/ Hypoglycemic Agents - therapeutic use
/ Infant
/ Insulin
/ Insulin - administration & dosage
/ insulin-dependent diabetes mellitus
/ Male
/ mothers
/ Safety
